CoChat
Sign Up
Cited by 22

The DOI matches its Crossref record.

Liver-targeted degradation of BRD4 reverses hepatic fibrosis and enhances metabolism in murine models

Yuan, Shengjie, Nisar, Ayesha, Chen, Chuanjie, Dong, Xin, Pan, Yongzhang, Zi, Meiting, Wang, Qiong, Khan, Sawar, Guo, Yaxun, Zhang, Xuan, He, Yonghan·2025·Theranostics
DOI 10.7150/thno.113852PMC PMC12315693
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7150/thno.113852

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 76

  1. [1]Kim JH Lee S Lee MY Shin HK Therapeutic effect of Soshiho-tang, a traditional herbal formula, on liver fibrosis or cirrhosis in animal models: a systematic review and meta-analysis J Ethnopharmacol 2014 154 1 16 24727191
  2. [2]Henderson NC Rieder F Wynn TA Fibrosis: from mechanisms to medicines Nature 2020 587 555 66 33239795 PMC8034822
  3. [3]Cordero-Espinoza L Huch M The balancing act of the liver: tissue regeneration versus fibrosis J Clin Invest 2018 128 85 96 29293095 PMC5749503
  4. [4]Somnay K Wadgaonkar P Sridhar N Roshni P Rao N Wadgaonkar R Liver Fibrosis Leading to Cirrhosis: Basic Mechanisms and Clinical Perspectives Biomedicines 2024 12 2229 39457542 PMC11505165
  5. [5]Hammerich L Tacke F Hepatic inflammatory responses in liver fibrosis Nat Rev Gastroenterol Hepatol 2023 20 633 46 37400694
  6. [6]Miao H Wu X-Q Zhang D-D Wang Y-N Guo Y Li P Deciphering the cellular mechanisms underlying fibrosis-associated diseases and therapeutic avenues Pharmacol Res 2021 163 105316 33248198
  7. [7]Di X Li Y Wei J Li T Liao B Targeting Fibrosis: From Molecular Mechanisms to Advanced Therapies Adv Sci (Weinh) 2025 12 e2410416 39665319 PMC11744640
  8. [8]European Association for the Study of the Liver EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection J Hepatol 2017 67 370 98 28427875
  9. [9]Tilg H Moschen AR Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis Hepatology 2010 52 1836 46 21038418
  10. [10]Sanyal AJ Chalasani N Kowdley KV McCullough A Diehl AM Bass NM Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis N Engl J Med 2010 362 1675 85 20427778 PMC2928471
  11. [11]Paschos P Tziomalos K Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment World J Hepatol 2012 4 327 31 23355909 PMC3554795
  12. [12]Cusi K Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis Clin Liver Dis 2009 13 545 63 19818304
  13. [13]Dooley S ten Dijke P TGF-β in progression of liver disease Cell Tissue Res 2012 347 245 56 22006249 PMC3250614
  14. [14]Parsons CJ Takashima M Rippe RA Molecular mechanisms of hepatic fibrogenesis J Gastroenterol Hepatol 2007 22 Suppl 1 S79 84 17567474
  15. [15]Meissner EG McLaughlin M Matthews L Gharib AM Wood BJ Levy E Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial Liver Int 2016 36 1783 92 27232579 PMC5116256
  16. [16]Barry-Hamilton V Spangler R Marshall D McCauley S Rodriguez HM Oyasu M Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment Nat Med 2010 16 1009 17 20818376
  17. [17]Baghaei K Mazhari S Tokhanbigli S Parsamanesh G Alavifard H Schaafsma D Therapeutic potential of targeting regulatory mechanisms of hepatic stellate cell activation in liver fibrosis Drug Discov Today 2022 27 1044 61 34952225
  18. [18]Dewidar B Meyer C Dooley S Meindl-Beinker AN TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis-Updated 2019 Cells 2019 8 1419 31718044 PMC6912224
  19. [19]Schwabe RF Tabas I Pajvani UB Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis Gastroenterology 2020 158 1913 28 32044315 PMC7682538
  20. [20]Deng Z Fan T Xiao C Tian H Zheng Y Li C TGF-β signaling in health, disease and therapeutics Signal Transduct Target Ther 2024 9 61 38514615 PMC10958066
  21. [21]Hinz B The extracellular matrix and transforming growth factor-β1: Tale of a strained relationship Matrix Biol 2015 47 54 65 25960420
  22. [22]Giarratana AO Prendergast CM Salvatore MM Capaccione KM TGF-β signaling: critical nexus of fibrogenesis and cancer J Transl Med 2024 22 594 38926762 PMC11201862
  23. [23]Wu C Cheng D Peng Y Li Y Fu C Wang Y Hepatic BRD4 Is Upregulated in Liver Fibrosis of Various Etiologies and Positively Correlated to Fibrotic Severity Front Med (Lausanne) 2021 8 683506 34336890 PMC8317578
  24. [24]Cheng M Li JJ Niu XN Zhu L Liu JY Jia PC BRD4 promotes hepatic stellate cells activation and hepatic fibrosis via mediating P300/H3K27ac/PLK1 axis Biochem Pharmacol 2023 210 115497 36907496
  25. [25]Xu F Lu S Pan N Zhao F Jia X Wang S Bromodomain protein 4 is a key molecular driver of TGFβ1-induced hepatic stellate cell activation Biochim Biophys Acta Mol Cell Res 2023 1870 119569 37597774
  26. [26]Wei Q Gan C Sun M Xie Y Liu H Xue T BRD4: an effective target for organ fibrosis Biomark Res 2024 12 92 39215370 PMC11365212
  27. [27]Thomas H Regulating profibrotic transcription Nat Rev Gastroenterol Hepatol 2016 13 62 3 26695083
  28. [28]Wang N Wu R Tang D Kang R The BET family in immunity and disease Signal Transduct Target Ther 2021 6 23 33462181 PMC7813845
  29. [29]Borck PC Guo LW Plutzky J BET Epigenetic Reader Proteins in Cardiovascular Transcriptional Programs Circ Res 2020 126 1190 208 32324495 PMC8111334
  30. [30]Bi T Liang P Zhao Q Wu J Zhou Y Xu Y Targeted Degradation of Bromodomain-Containing Protein 4 Enabled by Reactive Oxygen Species-Activatable NanoPROTACs as an Efficient Strategy to Reverse Liver Fibrosis in Chronic Liver Injury J Med Chem 2025 68 6328 6338 40045597
  31. [31]Hu J Pan D Li G Chen K Hu X Regulation of programmed cell death by Brd4 Cell Death Dis 2022 13 1059 36539410 PMC9767942
  32. [32]He Y Khan S Huo Z Lv D Zhang X Liu X Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies J Hematol Oncol 2020 13 103 32718354 PMC7384229
  33. [33]Bond MJ Crews CM Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation RSC Chem Biol 2021 2 725 42 34212149 PMC8190915
  34. [34]Liu Z Hu M Yang Y Du C Zhou H Liu C An overview of PROTACs: a promising drug discovery paradigm Mol Biomed 2022 3 46 36536188 PMC9763089
  35. [35]Békés M Langley DR Crews CM PROTAC targeted protein degraders: the past is prologue Nat Rev Drug Discov 2022 21 181 200 35042991 PMC8765495
  36. [36]Hines J Lartigue S Dong H Qian Y Crews CM MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53 Cancer Res 2019 79 251 62 30385614 PMC6318015
  37. [37]Sun X Gao H Yang Y He M Wu Y Song Y PROTACs: great opportunities for academia and industry Signal Transduct Target Ther 2019 4 64 31885879 PMC6927964
  38. [38]Churcher I Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones? J Med Chem 2018 61 444 52 29144739
  39. [39]Burke MR Smith AR Zheng G Overcoming Cancer Drug Resistance Utilizing PROTAC Technology Front Cell Dev Biol 2022 10 872729 35547806 PMC9083012
  40. [40]Chen C Pan Y Yang X Li H Cai X He S Liver-targeting chimeras as a potential modality for the treatment of liver diseases J Control Release 2024 374 627 38 39208934
  41. [41]Humbert A Lefebvre R Nawrot M Caussy C Rieusset J Calcium signalling in hepatic metabolism: Health and diseases Cell Calcium 2023 114 102780 37506596
  42. [42]Liu Y Qian M Li Y Dong X Wu Y Yuan T The ubiquitin-proteasome system: A potential target for the MASLD Acta Pharm Sin B 2025 15 1268 1280 40370547 PMC12069246
  43. [43]Fujii T Fuchs BC Yamada S Lauwers GY Kulu Y Goodwin JM Mouse model of carbon tetrachloride induced liver fibrosis: Histopathological changes and expression of CD133 and epidermal growth factor BMC Gastroenterol 2010 10 79 20618941 PMC2912240
  44. [44]Rocha SW de França ME Rodrigues GB Barbosa KP Nunes AK Pastor AF Diethylcarbamazine reduces chronic inflammation and fibrosis in carbon tetrachloride- (CCl₄-) induced liver injury in mice Mediators Inflamm 2014 2014 696383 25374445 PMC4211150
  45. [45]Zhang G Wang X Chung T-Y Ye W Hodge L Zhang L Carbon tetrachloride (CCl4) accelerated development of non-alcoholic fatty liver disease (NAFLD)/steatohepatitis (NASH) in MS-NASH mice fed western diet supplemented with fructose (WDF) BMC Gastroenterol 2020 20 339 33059584 PMC7560288
  46. [46]Van De Vlekkert D Machado E d'Azzo A Analysis of Generalized Fibrosis in Mouse Tissue Sections with Masson's Trichrome Staining Bio Protoc 2020 10 e3629 PMC7842772 33659302
  47. [47]Szász C Pap D Szebeni B Bokrossy P Őrfi L Szabó AJ Optimization of Sirius Red-Based Microplate Assay to Investigate Collagen Production In Vitro Int J Mol Sci 2023 24 17435 38139263 PMC10744033
  48. [48]Courtoy GE Leclercq I Froidure A Schiano G Morelle J Devuyst O Digital Image Analysis of Picrosirius Red Staining: A Robust Method for Multi-Organ Fibrosis Quantification and Characterization Biomolecules 2020 10 1585 33266431 PMC7709042
  49. [49]Arriazu E Ruiz de Galarreta M Cubero FJ Varela-Rey M Pérez de Obanos MP Leung TM Extracellular matrix and liver disease Antioxid Redox Signal 2014 21 1078 97 24219114 PMC4123471
  50. [50]Yang C Geng X Wan G Song L Wang Y Zhou G Transcriptomic and proteomic investigation of the ameliorative effect of total polyphenolic glycoside extract on hepatic fibrosis in Lamiophlomis rotata Kudo via the AGE/RAGE pathway J Ethnopharmacol 2024 324 117720 38211823
  51. [51]Matsumoto M Hada N Sakamaki Y Uno A Shiga T Tanaka C An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis Int J Exp Pathol 2013 94 93 103 23305254 PMC3607137
  52. [52]Lala V Zubair M Minter DA Liver Function Tests Treasure Island (FL): StatPearls Publishing 2025 29494096
  53. [53]Dhar D Baglieri J Kisseleva T Brenner DA Mechanisms of liver fibrosis and its role in liver cancer Exp Biol Med (Maywood) 2020 245 96 108 31924111 PMC7016420
  54. [54]Parola M Pinzani M Liver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies Mol Aspects Med 2024 95 101231 38056058
  55. [55]Roehlen N Crouchet E Baumert TF Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives Cells 2020 9 875 32260126 PMC7226751
  56. [56]Ding N Hah N Yu RT Sherman MH Benner C Leblanc M BRD4 is a novel therapeutic target for liver fibrosis Proc Natl Acad Sci U S A 2015 112 15713 8 26644586 PMC4697417
  57. [57]Xu L Hui AY Albanis E Arthur MJ O'Byrne SM Blaner WS Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis Gut 2005 54 142 51 15591520 PMC1774377
  58. [58]Yu J Hu Y Gao Y Li Q Zeng Z Li Y Kindlin-2 regulates hepatic stellate cells activation and liver fibrogenesis Cell Death Discov 2018 4 93 30245857 PMC6135746
  59. [59]Mori Y Akizuki Y Honda R Takao M Tsuchimoto A Hashimoto S Intrinsic signaling pathways modulate targeted protein degradation Nat Commun 2024 15 5379 38956052 PMC11220168
  60. [60]Wang Z-Q Zhang Z-C Wu Y-Y Pi Y-N Lou S-H Liu T-B Bromodomain and extraterminal (BET) proteins: biological functions, diseases and targeted therapy Signal Transduct Target Ther 2023 8 420 37926722 PMC10625992
  61. [61]Theodoulou NH Tomkinson NC Prinjha RK Humphreys PG Clinical progress and pharmacology of small molecule bromodomain inhibitors Curr Opin Chem Biol 2016 33 58 66 27295577
  62. [62]Middleton SA Rajpal N Cutler L Mander P Rioja I Prinjha RK BET Inhibition Improves NASH and Liver Fibrosis Sci Rep 2018 8 17257 30467325 PMC6250695
  63. [63]Shi J Vakoc Christopher R The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition Mol Cell 2014 54 728 36 24905006 PMC4236231
  64. [64]Nallagangula KS Nagaraj SK Venkataswamy L Chandrappa M Liver fibrosis: a compilation on the biomarkers status and their significance during disease progression Future Sci OA 2018 4 Fso250 29255622 PMC5729599
  65. [65]De Smet V Eysackers N Merens V Kazemzadeh Dastjerd M Halder G Verhulst S Initiation of hepatic stellate cell activation extends into chronic liver disease Cell Death Dis 2021 12 1110 34839349 PMC8627507
  66. [66]Fang T Wang H Pan X Little PJ Xu S Weng J Mouse models of nonalcoholic fatty liver disease (NAFLD): pathomechanisms and pharmacotherapies Int J Biol Sci 2022 18 5681 97 36263163 PMC9576517
  67. [67]Ipsen DH Lykkesfeldt J Tveden-Nyborg P Animal Models of Fibrosis in Nonalcoholic Steatohepatitis: Do They Reflect Human Disease? Adv Nutr 2020 11 1696 711 33191435 PMC7666900
  68. [68]Serban AI Stanca L Geicu OI Munteanu MC Dinischiotu A RAGE and TGF-β1 Cross-Talk Regulate Extracellular Matrix Turnover and Cytokine Synthesis in AGEs Exposed Fibroblast Cells PLoS One 2016 11 e0152376 27015414 PMC4807770
  69. [69]Song JS Kang CM Park CK Yoon HK Lee SY Ahn JH Inhibitory effect of receptor for advanced glycation end products (RAGE) on the TGF-β-induced alveolar epithelial to mesenchymal transition Exp Mol Med 2011 43 517 24 21743278 PMC3203242
  70. [70]Wang XL Yang M Wang Y Roles of transforming growth factor-β signaling in liver disease World J Hepatol 2024 16 973 9 39086528 PMC11287609
  71. [71]Fabregat I Moreno-Càceres J Sánchez A Dooley S Dewidar B Giannelli G TGF-β signalling and liver disease FEBS J 2016 283 2219 32 26807763
  72. [72]McQuitty CE Williams R Chokshi S Urbani L Immunomodulatory Role of the Extracellular Matrix Within the Liver Disease Microenvironment Front Immunol 2020 11 574276 33262757 PMC7686550
  73. [73]Karsdal MA Manon-Jensen T Genovese F Kristensen JH Nielsen MJ Sand JM Novel insights into the function and dynamics of extracellular matrix in liver fibrosis Am J Physiol Gastrointest Liver Physiol 2015 308 G807 30 25767261 PMC4437019
  74. [74]Zhang S Tuo P Ji Y Huang Z Xiong Z Li H Identification of 1-Methylnicotinamide as a specific biomarker for the progression of cirrhosis to hepatocellular carcinoma J Cancer Res Clin Oncol 2024 150 310 38890166 PMC11189347
  75. [75]Liang G Li Y Lin Y Yang X Yang J Hu S Nicotinamide N-methyltransferase and liver diseases Genes Dis 2023 10 1883 93 37492717 PMC10363563
  76. [76]Lai S Ma Y Hao L Ding Q Chang K Zhuge H 1-Methylnicotinamide promotes hepatic steatosis in mice: A potential mechanism in chronic alcohol-induced fatty liver disease Biochim Biophys Acta Mol Cell Biol Lipids 2023 1868 159286 36690322

Cited by

Sorted by citations

Metadata

Authors
Yuan, S., Nisar, A., Chen, C., Dong, X., Pan, Y., Zi, M., Wang, Q., Khan, S., Guo, Y., Zhang, X., & He, Y.
Venue
Theranostics
Publisher
Ivyspring International Publisher
Published
2025-06-18
Volume
15
Issue
15
Pages
7270-7290
ISSN
1838-7640
DOI
10.7150/thno.113852
PMC
PMC12315693
Cited by
22
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review